JP2024521706A5 - - Google Patents
Info
- Publication number
- JP2024521706A5 JP2024521706A5 JP2023571805A JP2023571805A JP2024521706A5 JP 2024521706 A5 JP2024521706 A5 JP 2024521706A5 JP 2023571805 A JP2023571805 A JP 2023571805A JP 2023571805 A JP2023571805 A JP 2023571805A JP 2024521706 A5 JP2024521706 A5 JP 2024521706A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- group
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191631P | 2021-05-21 | 2021-05-21 | |
| US63/191,631 | 2021-05-21 | ||
| PCT/US2022/030227 WO2022246177A1 (en) | 2021-05-21 | 2022-05-20 | Axl compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024521706A JP2024521706A (ja) | 2024-06-04 |
| JP2024521706A5 true JP2024521706A5 (https=) | 2025-05-27 |
| JP7843299B2 JP7843299B2 (ja) | 2026-04-09 |
Family
ID=82115693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571805A Active JP7843299B2 (ja) | 2021-05-21 | 2022-05-20 | Ａｘｌ化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240246967A1 (https=) |
| EP (1) | EP4341261A1 (https=) |
| JP (1) | JP7843299B2 (https=) |
| CN (1) | CN117295741A (https=) |
| TW (1) | TW202313602A (https=) |
| WO (1) | WO2022246177A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129722A1 (es) * | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119768155A (zh) | 2022-09-14 | 2025-04-04 | 艾库斯生物科学有限公司 | 依曲地南的分散体 |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024249894A2 (en) | 2023-06-02 | 2024-12-05 | Arcus Biosciences, Inc. | Biomarkers for predicting cancer treatment efficacy |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2025137370A1 (en) * | 2023-12-20 | 2025-06-26 | Arcus Biosciences, Inc. | Salt forms of an axl inhibitor |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2017120508A1 (en) | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| EP3518934A4 (en) | 2016-10-03 | 2020-06-24 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| WO2018094148A1 (en) | 2016-11-18 | 2018-05-24 | Arcus Biosciences, Inc. | Inhibitors of cd73-mediated immunosuppression |
| HUE064141T2 (hu) | 2017-01-20 | 2024-02-28 | Arcus Biosciences Inc | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére |
| ES2953349T3 (es) | 2017-05-05 | 2023-11-10 | Arcus Biosciences Inc | Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer |
| PL3829581T3 (pl) | 2018-07-27 | 2024-07-01 | Arcus Biosciences, Inc. | Antagoniści pirydonu a2r |
| WO2020046813A1 (en) | 2018-08-27 | 2020-03-05 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| TWI828800B (zh) | 2018-11-16 | 2024-01-11 | 美商阿克思生物科學有限公司 | Arg1及/或arg2之抑制劑 |
| WO2020103896A1 (en) * | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof |
| CN114206332B (zh) | 2019-06-04 | 2024-08-23 | 艾库斯生物科学有限公司 | 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物 |
| TWI848141B (zh) * | 2019-07-04 | 2024-07-11 | 英屬開曼群島商百濟神州有限公司 | 及其用途 |
| JP2023504623A (ja) | 2019-12-04 | 2023-02-06 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ｈｉｆ－２アルファの阻害剤 |
| CN119118872A (zh) | 2020-03-19 | 2024-12-13 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
-
2022
- 2022-05-20 EP EP22731889.6A patent/EP4341261A1/en active Pending
- 2022-05-20 CN CN202280034430.8A patent/CN117295741A/zh active Pending
- 2022-05-20 WO PCT/US2022/030227 patent/WO2022246177A1/en not_active Ceased
- 2022-05-20 TW TW111118926A patent/TW202313602A/zh unknown
- 2022-05-20 JP JP2023571805A patent/JP7843299B2/ja active Active
- 2022-05-20 US US18/555,963 patent/US20240246967A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521706A5 (https=) | ||
| JP2024521712A5 (https=) | ||
| JP2023518286A5 (https=) | ||
| JP7203964B2 (ja) | 統合的ストレス経路のプロドラッグ調節剤 | |
| JP2022535120A5 (https=) | ||
| JP2022538228A5 (https=) | ||
| TWI838350B (zh) | 抗癌劑 | |
| JP2016506916A5 (https=) | ||
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2021523112A5 (https=) | ||
| CN105683201B (zh) | 新的含n‑杂环碳烯配体的金(iii)络合物、合成及其在癌症治疗和硫醇检测中的应用 | |
| JP2020510032A5 (https=) | ||
| JP2018504418A5 (https=) | ||
| JP2022507065A5 (https=) | ||
| JP2022520061A5 (https=) | ||
| JP2015520143A5 (https=) | ||
| JP2025525364A5 (https=) | ||
| RU2015141772A (ru) | Новые соединения и композиции для ингибирования fasn | |
| JP2019515952A5 (https=) | ||
| JP2012158602A5 (https=) | ||
| JP2017517548A5 (https=) | ||
| JP2024541969A5 (https=) | ||
| JP6198286B2 (ja) | 癌の処置のためのイソフラボノイド化合物および方法 | |
| Sau et al. | Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug | |
| RU2017112048A (ru) | Синергистические комбинации ауристана |